Rectal doses in intracavitary brachytherapy of gynecological malignancies: comparison of two dosimetric methods

Interfraction Variation and Dosimetric Changes in Patients With Cervical Cancer Treated With Intracavitary Brachytherapy

PURPOSE

Intracavitary brachytherapy is integral in the treatment of cervical cancer. Because of interfraction variation, the current standard is replanning with every fraction. This study aimed to determine whether there was a difference in relative dosimetry if the source position and dwell time of the first fraction were applied to subsequent fractions.

MATERIALS AND METHODS

The authors performed a retrospective review of charts and films from 2007 to 2012. Eligible cases were patients with cervical cancer treated with brachytherapy with the same dose prescription to point A. Replanning was done on the first set of orthogonal plates. Source position and dwell time were subsequently applied to the remaining fractions using actual films.

RESULTS

Twenty-nine patients were included in this study. The results showed that cervical, rectal, and bladder dose between the actual plan and the hypothetical plan were not statistically different. In the hypothetical plan, the source activity and dwell time of the first plan were applied to the orthogonal films of the subsequent fractions and showed no significant difference in all dose points.

CONCLUSION

The results of this study showed proof of concept of the safety of using the source position and dwell time of the first plan for subsequent fractions. Until further studies are performed (also using three-dimensional planning software), the concept should be considered investigational because of the small sample size of the study. Until such research is performed, it is still strongly recommended that replanning be performed with every fraction whenever it is feasible.

Assessment of cartesian co-ordinates-based bladder and rectal dose and variability with tandem-ring angles first Nigerian experience in high-dose-rate brachytherapy

OBJECTIVE:

This study assessed bladder and rectal dose based on Cartesian-coordinates in intracavitary brachytherapy and examined the variations resulting from use of tandem-ring (T-R) of different angles.

METHODS:

Cartesian-co-ordinates of bladder and rectum points were derived on orthogonal-radiographs of 90 patients who had high-dose-rate brachytherapy for cervical cancer at the Department of Radiation Oncology, University College Hospital, Ibadan, Nigeria. The patients were classified in three groups of 30, based on T-R angles 30°, 45° and 60° used, bearing same lengths and diameters across sets. The measured co-ordinates and the related percentage doses to points of interest in the two organs were analysed using EViews and SPSS statistical softwares.

RESULTS:

The mean rectal point dose (RPD) obtained was 68.97 ± 13.57 % of the prescribed doses as against 56.57 ± 11.83% for bladder point dose. While the maximums of the mean RPD were 95.7, 90.5 and 82.5% for T-R angles 30°, 45° and 60° respectively; corresponding values for the bladder point were 72.8, 87.8 and 62.3%.

CONCLUSION:

The baseline data obtained in this study served as guidelines for subsequently achieving acceptable values of bladder point dose and RPD at University College Hospital, Nigeria. Special attention should be paid to the application of 2 cm-tandems in relation to the RPD.

ADVANCES IN KNOWLEDGE:

This is one of the few studies assessing the influence of T-R angles on organs-at-risk. The increase in RPD with the use of intrauterine tandem-2 cm is found to be most pronounced with T-R 30⁰, and this trend reduced with larger angles.

In vivo dosimetry with semiconductors in medium dose rate (MDR) brachytherapy for cervical cancer

PURPOSE

This study was performed to evaluate the role of in vivo dosimetry with semiconductor detectors in gynaecological medium dose rate brachytherapy, and to compare the actual doses delivered to organs at risk (as measured using in vivo dosimetry) with those calculated during treatment planning.

MATERIALS AND METHODS

Doses to the rectum and bladder were measured in a group of patients with cervical carcinoma using semiconductor detectors and compared to the doses calculated using a treatment planning system. 36 applications of brachytherapy at dose rates of 1.8-2.3 Gy/h were performed in the patients.

RESULTS

The mean differences between the measured and calculated doses were 3 % for the rectum and 11 % for the bladder.

CONCLUSIONS

The main reason for the differences between the measured and calculated doses was patient movement. To reduce the risk of large errors in the dose delivered, in vivo dosimetry should be performed in addition to treatment planning system computations.

Evaluation of treatment planning system of brachytherapy according to dose to the rectum delivered

The aim of this study was to assess the actual dose delivered to the rectum and compare it with the treatment planning system (TPS) reports. In this study, the dose delivered to the rectum was measured by semiconductor diode detectors (PTW, Germany). The factors that influence diode response were investigated as well. Calibration factors of diodes were measured weekly to investigate the effect of time interval on the accuracy of calibration. Then 40 applications of patients with cervix carcinoma were evaluated. Rectum dose was measured by means of rectal dosemeter and compared with the TPS-calculated dose. In this research, the differences between the measured and the calculated dose were investigated. The mean difference between the TPS-calculated dose and the measured dose was 6.5% (range: -22 to +39) for rectum. The TPS-calculated maximum dose was typically higher than the measured maximum dose. The study showed that the main reason for the difference was due to the movements of the patient and applicator shift in the elapsed time between the imaging and treatment stage. It is recommended that in vivo dosimetry should be performed in addition to treatment planning computation. In vivo dosimetry is a reliable solution to compare the planned and actual dose delivered to organs at risk.

Rectal dosimetry in intracavitary brachytherapy by HDR at rural center of Maharashtra: Comparison of two methods

The purpose of this study was to calculate the radiation dose at the anterior rectal wall as per the International Commission on Radiation Units and Measurements (ICRU 38) recommendations and compare it with the dose calculated by the commonly used intrarectal catheter. Dose delivery by brachytherapy to the cervix is limited by the critical structure of the bladder and rectum. In this study the ICRU-38 rectal point was derived by using a radio-opaque gauze piece on the posterior vaginal wall, and the intrarectal point was derived by inserting a rubber catheter with a wire, inside the rectum. A total of 146 applications were performed in 81 patients. Rectal doses were compared for complementary rectal points R1 and R5, R2 and R6, R3 and R7, and R4 and R8, obtained by both methods. The rectal doses at each complementary pair were compared with each other. The average dose at R1 was 5% higher than at R5 (60.57% vs. 55.57%). The average dose at R2 was 1% higher than at R6 (58% vs. 57%). The average dose at R3 was 1.29% higher than at R7 (52.71% vs. 51.42%), and the average dose at R4 was 1.15% higher than at R8 (43% vs. 41.85%). There were many instances where the rectal dose exceeded by more than 15%, from the R1 to R4 points (43, 22, 21, and 11 times, respectively, for R1-R5, R2-R6, R3-R7, and R4-R8 pairs). The difference in dose between R1 and R5 was significant as seen on the statistical tests, i.e., Pair T test, Wilcoxan Signed Ranks test, and Sign test (p value 0.002). The rectal dose obtained by the intrarectal wire method underestimates the actual dose to the rectum when compared to the ICRU-38 method. Thus ICRU-38 recommendations should be strictly adhered to, to reduce late complications.

Variability of marker-based rectal dose evaluation in HDR cervical brachytherapy

In film-based intracavitary brachytherapy for cervical cancer, position of the rectal markers may not accurately represent the anterior rectal wall. This study was aimed at analyzing the variability of rectal dose estimation as a result of interfractional variation of marker placement. A cohort of five patients treated with multiple-fraction tandem and ovoid high-dose-rate (HDR) brachytherapy was studied. The cervical os point and the orientation of the applicators were matched among all fractional plans for each patient. Rectal points obtained from all fractions were then input into each clinical treated plan. New fractional rectal doses were obtained and a new cumulative rectal dose for each patient was calculated. The maximum interfractional variation of distances between rectal dose points and the closest source positions was 1.1 cm. The corresponding maximum variability of fractional rectal dose was 65.5%. The percentage difference in cumulative rectal dose estimation for each patient was 5.4%, 19.6%, 34.6%, 23.4%, and 13.9%, respectively. In conclusion, care should be taken when using rectal markers as reference points for estimating rectal dose in HDR cervical brachytherapy. The best estimate of true rectal dose for each fraction should be determined by the most anterior point among all fractions.

Reconstruction of a ring applicator using CT imaging: impact of the reconstruction method and applicator orientation

The purpose of this study is to investigate whether the method of applicator reconstruction and/or the applicator orientation influence the dose calculation to points around the applicator for brachytherapy of cervical cancer with CT-based treatment planning. A phantom, containing a fixed ring applicator set and six lead pellets representing dose points, was used. The phantom was CT scanned with the ring applicator at four different angles related to the image plane. In each scan the applicator was reconstructed by three methods: (1) direct reconstruction in each image (DR), (2) reconstruction in multiplanar reconstructed images (MPR) and (3) library plans, using pre-defined applicator geometry (LIB). The doses to the lead pellets were calculated. The relative standard deviation (SD) for all reconstruction methods was less than 3.7% in the dose points. The relative SD for the LIB method was significantly lower (p < 0.05) than for the DR and MPR methods for all but two points. All applicator orientations had similar dose calculation reproducibility. Using library plans for applicator reconstruction gives the most reproducible dose calculation. However, with restrictive guidelines for applicator reconstruction the uncertainties for all methods are low compared to other factors influencing the accuracy of brachytherapy.

Changes in applicator positions and dose distribution between high dose rate brachytherapy fractions in cervix carcinoma patients receiving definitive radiotherapy

This study examines the change of applicator geometry and its effect on rectal/rectum (R) and bladder (B) doses, and obtained radiobiological equivalent doses (RED), between each high dose rate (HDR) brachytherapy (BT) fraction in cervical carcinoma patients. BT using a tandem (T) and two ovoids (O) is included, and any discrepancies in applicator positions among the fractions were calculated. Whether the change of applicator position had an effect on the calculated R and B doses was analysed. Furthermore, the relationship between the size of tumour, the magnitude of displacement and the change in R and B doses was also investigated. Lastly, the changes in R and B RED were noted. The average magnitude of displacement was between 2.0 mm and 16.9 mm, showing time trend. There was no relationship between tumour size and the magnitude of discrepancy of Left O, Right O, T, R, B, and neither change in R and B doses (p>0.05). The mean differences of R and B doses were between 49-78 cGy, and 70-84 cGy, respectively. The magnitude of discrepancy and changes in doses showed no correlation (p>0.05). There were no significant differences in REDs for bladder (p = 0.8) and rectum (p = 0.2). In conclusion, there were significant differences in the applicator positions R and B and R and B doses among the fractions, which confirm the necessity of treatment planning in each HDR BT fraction. However, the total calculated R and B REDs did not show a remarkable difference.

EPR/alanine dosimetry in LDR brachytherapy--a feasibility study

In this study, we present the results of in vivo dosimetry, using electron paramagnetic resonance in l-alanine, performed on 13 patients treated for gynaecological cancers. The doses from (137)Cs (12 samples) and (192)Ir (one sample) brachytherapy sources were determined inside vagina. The detectors had a form of small cellulose capsules tightly filled with crystalline alanine. The positions of the detectors were reconstructed from two orthogonal radiographs. The planned doses were calculated with a computer planning system (PLATO, Nucletron). The relative deviations between planned and measured doses ranged from -23 to +14%. The mean deviation from the prescribed dose was relatively low (-5%) with SD of 10%. The main sources of differences between the measured and calculated doses were attributed to uncertainty in the determination of the detector position inside the patient's body and to uncontrolled changes in the detector position during the treatment.

[Pulse Dose Rate brachytherapy: optimization and place of imaging]

Pulse Dose Rate (PDR) brachytherapy presents the potential radiobiological advantages of low dose rate and the technical and radiation protection advantages of high dose rate remote afterloading technology. The different algorithms provided by the treatment planning systems allow dose rate and isodose shape optimization regarding the volumes defined by the radiologist and the radiation oncologist. The contribution of imaging together with these new optimization tools should improve brachytherapy practice and the therapeutic ratio. These new evolutions of brachytherapy will be presented here.

Rectal dosimetry in intracavitary applications of cervix carcinoma: Comparison of two methods

BACKGROUND: Brachytherapy of cervix carcinoma often results in high doses to surrounding structures, such as rectum and bladder. Therefore, these organs should be closely monitored. Purpose of this work was to evaluate rectal marker made in our institution for rectal dose measurements by comparing it with the method recommended in ICRU (International Commission on Radiation Units and Measurements) Report 38. METHODS: In this work rectal dosimetry was performed by two different methods. In one, rectal marker made in Institute of Oncology Sremska Kamenica was used, while in the other method recommended in ICRU Report 38 dose on ICRU rectal point was measured A total of 34 applications using Microselectron HDR and its standard applicator set were performed in a prospective way. The prescribed dose was 7.6 Gy to point A for each application. Rectal doses were calculated by Nucletron Plato Treatment Planning System. RESULTS: Differences found between the means of ICRU point R and rectal marker points Rref and Rmax were significant (P<0.002 and P<0.00002). The same result was obtained for Rref and Rmax pair (P<0.003). CONCLUSION: Maximal doses obtained using rectal marker were in most cases high- er than those obtained by ICRU method. It conforms well to several CT-based dosimetry studies where rectum dose was found to be higher from that obtained by ICRU method.